research Distribution of SALT Scores by Therapeutic Response in Patients with Severe Alopecia After 52 Weeks of Baricitinib Therapy
Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.
Search
for
Sort by
Research
60-90 / 399 results 
research Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Treated With Baricitinib: An Update Through Week 152 From BRAVE-AA2
Reducing the dose of Baricitinib to 2mg still helped over half of the patients with severe scalp alopecia maintain their hair regrowth after two years.
research Improvement in Health-Related Quality of Life and Symptoms of Anxiety and Depression in Patients with Alopecia Areata Randomized to Baricitinib or Placebo: Results from Two International Randomized Controlled Trials
Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.
research Dupilumab Therapy for Alopecia Areata in a 4-Year-Old Patient Resistant to Baricitinib
Dupilumab helped a 4-year-old grow hair back after another treatment failed.
research Efficacy and Safety of Baricitinib in Patients With Alopecia Areata: Evidence to Date
Baricitinib is a promising treatment for alopecia areata.
research Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data
Baricitinib effectively regrows hair in most people with severe alopecia, especially those with patchy hair loss, but hair may fall out again if treatment stops.
research Expecting Scalp Hair Regrowth During Severe Alopecia Areata Treatment with Baricitinib: Insights from Patient Trajectories in Phase III Trials
Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.
research Review of Baricitinib in the Treatment of Alopecia Areata
Baricitinib is a relatively safe and effective treatment for severe alopecia areata.
research Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2
Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.
research Early Real-World Experience With Baricitinib in the Treatment of Severe Alopecia Areata
Baricitinib shows promise in treating severe hair loss.
research Concurrent Improvement in Scalp Hair and Eyebrow or Eyelash Regrowth in Patients With Severe Alopecia Areata Treated With Baricitinib
Baricitinib treatment can help regrow scalp hair and eyebrows or eyelashes in people with severe alopecia areata.
research Baseline Distribution of Eyebrow and Eyelash Loss by Severity of Scalp Hair Loss in Phase 3 Trials of Baricitinib for Alopecia Areata
The document's conclusion cannot be provided because the content is not available.
research The Development of Oral Hairy Leukoplakia During JAK Inhibitor Baricitinib Therapy
A man developed oral hairy leukoplakia while on baricitinib, a medication for alopecia and arthritis, and doctors should watch for such side effects.
research Combination of Baricitinib and Conventional Immunomodulating Therapy for Alopecia Totalis
Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.
research Major Improvement of Very Severe Alopecia Areata in Patients Treated With the Combination of Baricitinib and Low Doses of Corticosteroids: An Eight-Case Series
Combining baricitinib with low-dose corticosteroids significantly improved severe hair loss in eight patients.
research Efficacy and Safety of Baricitinib in Managing Severe Alopecia Areata: A 6-Month Real-World Experience
Baricitinib was effective and safe for severe hair loss treatment over 6 months.
research Efficacy of Baricitinib in Patients With Different Degrees of Severe Alopecia Areata: 52-Week Results From BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
research Review of Efficacy of Baricitinib in the Treatment of Alopecia Areata
Baricitinib is a promising treatment for severe alopecia areata with minimal side effects.
research Impact of Baricitinib on Work Productivity and Indirect Costs in Adult Patients with Atopic Dermatitis: A Meta-Analysis of Clinical Trials
Baricitinib at 2mg and 4mg doses improved work productivity and reduced costs for adults with atopic dermatitis.
research Baricitinib For Alopecia Areata
Baricitinib is effective in promoting hair growth in severe alopecia areata.
research Switching Between Tofacitinib and Baricitinib in Alopecia Areata: A Review of Clinical Response
Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.
research Treatment of Moderate-to-Severe Alopecia Areata in Adolescents With Baricitinib: A Retrospective Review of 29 Patients
Baricitinib helped most teenagers with severe hair loss regrow hair and had mild side effects.
research Ideal JAK Inhibitor for Alopecia Areata: Baricitinib, Tofacitinib, Ritlecitinib, or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway
No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
research Clinician and Patient Evaluation of Improvement for Eyebrow and Eyelashes Hair Loss During Baricitinib Phase 3 Trials BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.
research EE325 Budget Impact of Baricitinib for Patients with Severe Alopecia Areata
Adding Baricitinib for severe alopecia areata will have a small impact on a health plan's budget.
research Olumiant (Baricitinib): A Newly Approved Janus Kinase Inhibitor for the Treatment of Alopecia Areata
Olumiant® (Baricitinib) is effective for treating hair loss from Alopecia Areata.
research Experience with Tofacitinib and Baricitinib in Rheumatoid Arthritis
Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.